DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective - Bleeding-Disorders Edition" report has been added to ResearchAndMarkets.com's offering.
State of relationships between bleeding-disorders patient groups and the pharmaceutical industry
The worldwide incidence of one of the most high profile of the bleeding disorders - haemophilia - is not well known. However, the US-based Centers for Disease Control (CDC) estimates that this particular condition affects more than 400,000 people, with as many as 75% of these individuals (mostly people living in poorer parts of the world) still receiving inadequate treatment for their bleeding disorder - or, indeed, no access to treatment at all. A large number of the comments made to the 2017 Corporate-Reputation survey by respondent bleeding-conditions patient groups underscored the problems associated with significant worldwide geographic inequities of bleeding-disorders treatments.
Patient groups which specialise in such conditions have particularly high expectations of the pharma companies that deliver treatments for bleeding disorders. These patient groups asked for pharmaceutical companies to put more effort into socially-responsible activities, and to be especially sensitive to the needs of patients with a bleeding condition.
Key Topics Covered:
- Executive Summary
- The Relationships That Bleeding-Disorders Patient Groups Have With Pharma, 2017
- Industry-Wide Findings From Bleeding-Disorders Patient Groups, 2017
- Rankings Of The 9 Pharma Companies, 2017 V. 2016 Among Bleeding-Disorders Patient Groups Familiar With The Companies
- Positioning Of 5 Pharma Companies, 2017 V. 2016 Among Bleeding-Disorders Patient Groups That Work/Partner With The Companies
- Profiles Of The 9 Companies, 2017
Companies Mentioned
- Bayer
- Biogen
- CSL Behring
- Grifols
- Novo Nordisk
- Octapharma
- Pfizer
- Roche/Genentech
- Shire
For more information about this report visit https://www.researchandmarkets.com/research/8dbjwf/corporate?w=4
